A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation
Interventions: DRUG: talazoparib|DRUG: Physician's-Choice
Sponsor: Pfizer
Collaborators: Medivation, Inc.